Intellipharmaceutics (NASDAQ:IPCI) shares traded 3.54% up during most recent session to reach at the closing price of $0.26. The stock exchanged hands 206573 shares versus average trading capacity of 1.09 Million shares, yielding a market cap of $5.33 Million. Wall Street analysts covering the stock are projecting that the stock will reach $27.5 within the next 52-weeks. The mean target projections are based on 2 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Intellipharmaceutics (NASDAQ:IPCI) high price target of $30 and with a conservative view have low price target of $25.

Maxim Group “Terminates” Intellipharmaceutics (NASDAQ:IPCI) in a research note issued to investors on 6/15/18 to Hold with price target of $0.

Additionally on 1/19/18 H.C. Wainwright “Initiates Coverage On” Intellipharmaceutics (NASDAQ:IPCI) to Buy setting price target at $2.5 and on 10/03/16 Brean Capital “Assumes” the stock to Buy at $8. Furthermore on 7/09/15 Maxim Group “Maintained” the stock to Buy at $8.

On the other hand the company has Relative Strength Index (RSI 14) of 40.75 along with Average True Range (ATR 14) of 0.04, Consequently Intellipharmaceutics (NASDAQ:IPCI)’s weekly and monthly volatility is 11.95%, 12.63% respectively. The company’s beta value is at 2.22.

In terms of Buy, Sell or Hold recommendations, Intellipharmaceutics (NASDAQ:IPCI) has analysts’ mean recommendation of 2. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Intellipharmaceutics (NASDAQ:IPCI)’s minimum EPS for the current quarter is at $-0.4 and can go high up to $-0.4. The consensus mean EPS for the current quarter is at $-0.4 derived from a total of 1 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.8 earnings per share for the same quarter during last year.

Previously Intellipharmaceutics (NASDAQ:IPCI) reported $-0.7 earnings per share (EPS) for the quarter, meeting the consensus estimate of $-0.7 by $0. The company posted an earnings surprise of 0%.

Intellipharmaceutics (NASDAQ:IPCI)’s revenue estimates for the current quarter are $1.89 Million according to 1 number of analysts, for the current quarter the company has high revenue estimates of $1.89 Million in contradiction of low revenue estimates of $1.89 Million. For the current year the company’s revenue estimates are $7 Million compared to low analyst estimates of $7 Million and high estimates of $7 Million according to 1 number of analysts.

Currently Intellipharmaceutics (NASDAQ:IPCI)’s shares owned by insiders are 56.5%, whereas shares owned by institutional owners are 0.5%. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded -5.59%.

Intellipharmaceutics (NASDAQ:IPCI)’s trailing twelve month revenues are $1.7 Million, whereas its price to sales ratio for the same period is 3.13. Its book value per share for the most recent quarter is $0.58 while its price to book ratio for the same period is 0.45, as for as the company’s cash per share for the most recent quarter is $0.33, however its price to cash per share ratio for the same period is 0.81. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.